Shock — Classification and Management

Shock is a life-threatening circulatory failure characterized by inadequate tissue perfusion and oxygen delivery, leading to cellular dysfunction and potential organ failure. The fundamental pathophysiology involves an imbalance between oxygen supply and demand at the cellular level, resulting in anaerobic metabolism, lactate accumulation, and metabolic acidosis.

Basic Hemodynamic Parameters:

• Mean Arterial Pressure (MAP) = Diastolic BP + 1/3(Systolic BP - Diastolic BP)
• Cardiac Output (CO) = Heart Rate × Stroke Volume
• Systemic Vascular Resistance (SVR) = (MAP - CVP) × 80 / CO
• Normal values: MAP >65 mmHg, CO 4-8 L/min, SVR 800-1200 dynes·sec/cm⁵

Shock progresses through three distinct phases: compensated (normal blood pressure with increased heart rate), uncompensated (hypotension develops), and irreversible (multiorgan failure despite intervention). Early recognition and intervention during the compensated phase significantly improve outcomes.

Clinical Manifestations:

• Hypotension (systolic BP <90 mmHg or MAP <65 mmHg)
• Tachycardia (>100 bpm in adults)
• Altered mental status
• Decreased urine output (<0.5 mL/kg/hr)
• Cool, clammy skin (except distributive shock)
• Prolonged capillary refill (>2 seconds)

Laboratory Findings:

• Elevated lactate (>2 mmol/L indicates tissue hypoperfusion)
• Metabolic acidosis (pH <7.35, HCO₃⁻ <22 mEq/L)
• Elevated creatinine and BUN
• Decreased mixed venous oxygen saturation (SvO₂ <70%)

The classification of shock into four main categories—hypovolemic, cardiogenic, distributive, and obstructive—is based on underlying pathophysiologic mechanisms and guides appropriate management strategies.

Hypovolemic shock results from inadequate circulating blood volume due to fluid loss, leading to decreased venous return, reduced preload, and subsequently diminished cardiac output. This represents the most common type of shock encountered in clinical practice.

Etiology:

• Hemorrhagic: Trauma, GI bleeding, surgical blood loss, ruptured aneurysm
• Non-hemorrhagic: Dehydration, burns, third-spacing (pancreatitis, bowel obstruction), excessive diuresis

Hemodynamic Profile:

• Decreased preload (CVP <8 mmHg)
• Decreased cardiac output
• Increased SVR (compensatory vasoconstriction)
• Decreased pulmonary capillary wedge pressure (PCWP <12 mmHg)

Clinical Assessment: Classification by percentage of blood volume lost:

• Class I (≤15%): Minimal symptoms, normal vital signs
• Class II (15-30%): Tachycardia, normal BP, anxiety
• Class III (30-40%): Hypotension, altered mental status
• Class IV (≥40%): Profound shock, unconsciousness

Management Algorithm:

Hypovolemic Shock Management ↓ Secure airway + O₂ ↓ Establish 2 large-bore IVs ↓ Fluid resuscitation: • Crystalloids: 20 mL/kg bolus • Blood products if hemorrhagic ↓ Monitor response: • Urine output >0.5 mL/kg/hr • Improved mental status • Lactate clearance ↓ Control source: • Stop bleeding • Replace ongoing losses

Fluid Resuscitation:

• Initial: 1-2 L crystalloid (normal saline or lactated Ringer's)
• Hemorrhagic shock: Massive transfusion protocol (1:1:1 ratio of packed RBCs:FFP:platelets)
• Target hemoglobin: 7-9 g/dL (70-90 g/L) in most patients
• Avoid over-resuscitation to prevent complications

Cardiogenic shock occurs when the heart cannot pump effectively to maintain adequate cardiac output, despite adequate preload. This condition carries the highest mortality among shock types, with rates exceeding 40-50% even with optimal treatment.

Etiology:

• Acute: Myocardial infarction (most common), acute mitral regurgitation, ventricular septal rupture, papillary muscle rupture
• Chronic: End-stage heart failure, cardiomyopathy, severe valvular disease
• Arrhythmic: Sustained ventricular tachycardia, complete heart block
• Other: Myocarditis, toxic cardiomyopathy, stress cardiomyopathy

Hemodynamic Profile:

• Decreased cardiac output (<2.2 L/min/m²)
• Elevated PCWP (>18 mmHg)
• Elevated CVP (>12 mmHg)
• Variable SVR (often elevated)
• Cardiac index <2.2 L/min/m²

Diagnostic Criteria:

• Systolic BP <90 mmHg for >30 minutes
• Cardiac index <2.2 L/min/m² without support or <2.5 L/min/m² with support
• PCWP >15 mmHg
• Signs of end-organ hypoperfusion

Management Strategy:

Cardiogenic Shock Management ↓ Immediate assessment: • ECG, echocardiography • Hemodynamic monitoring ↓ Revascularization if STEMI: • Primary PCI within 90 min • Thrombolytics if PCI unavailable ↓ Inotropic support: • Dobutamine 2.5-20 μg/kg/min • Milrinone 0.125-0.75 μg/kg/min ↓ Mechanical support if refractory: • IABP (intra-aortic balloon pump) • Impella, ECMO, ventricular assist devices

Pharmacologic Management:

• Dobutamine: First-line inotrope, increases contractility and heart rate
• Milrinone: Phosphodiesterase inhibitor, positive inotrope with vasodilation
• Norepinephrine: If profound hypotension (MAP <65 mmHg)
• Avoid: Dopamine (increased mortality), excessive fluid administration

Mechanical Circulatory Support: Indicated when pharmacologic therapy fails to maintain adequate perfusion. Options include IABP, percutaneous ventricular assist devices, and extracorporeal membrane oxygenation (ECMO).

Distributive shock is characterized by profound vasodilation leading to maldistribution of blood flow, despite normal or increased cardiac output. The primary pathophysiology involves loss of vascular tone due to various inflammatory or neurologic processes.

Subtypes and Etiology:

Septic Shock (most common):

• Systemic infection with SIRS criteria
• Gram-positive, gram-negative bacteria, fungi, viruses
• Endotoxin-mediated inflammatory cascade
• Definition: Sepsis + vasopressor requirement + lactate >2 mmol/L

Neurogenic Shock:

• Spinal cord injury above T6 level
• Loss of sympathetic nervous system control
• Characteristic: Hypotension with bradycardia

Anaphylactic Shock:

• IgE-mediated hypersensitivity reaction
• Massive histamine and mediator release
• Rapid onset after allergen exposure

Hemodynamic Profile:

• Decreased SVR (<800 dynes·sec/cm⁵)
• Normal or increased cardiac output
• Normal or low PCWP
• Wide pulse pressure
• Warm, vasodilated periphery (early septic shock)

Septic Shock Management:

Septic Shock Protocol ↓ Hour 1 Bundle: • Blood cultures before antibiotics • Broad-spectrum antibiotics • Lactate measurement • Fluid resuscitation: 30 mL/kg crystalloid ↓ If hypotension persists: • Vasopressors (norepinephrine first-line) • Target MAP ≥65 mmHg ↓ Source control: • Drainage, debridement • Remove infected devices ↓ Adjunctive therapies: • Corticosteroids if refractory • Consider activated protein C in selected cases

Vasopressor Selection:

• Norepinephrine: First-line, α₁ and β₁ agonist
• Vasopressin: Second-line, 0.01-0.04 units/min
• Dopamine: Alternative if low heart rate
• Epinephrine: Refractory shock
• Phenylephrine: Pure α-agonist, if tachyarrhythmias

Anaphylactic Shock Treatment:

• Epinephrine 0.3-0.5 mg IM (first-line)
• IV fluid resuscitation
• H₁ and H₂ antihistamines
• Corticosteroids
• Bronchodilators if bronchospasm

Obstructive shock results from physical obstruction to venous return or cardiac output, leading to inadequate tissue perfusion despite normal cardiac function. Rapid recognition and intervention are crucial as these conditions are often immediately life-threatening but potentially reversible.

Major Causes:

Pulmonary Embolism (PE):

• Massive PE obstructing >50% pulmonary circulation
• Hemodynamics: Elevated right heart pressures, decreased left ventricular filling
• Clinical: Sudden dyspnea, chest pain, hypotension, right heart strain on ECG

Tension Pneumothorax:

• Progressive air accumulation in pleural space
• Mediastinal shift compressing vena cava
• Clinical: Absent breath sounds, tracheal deviation, JVD

Cardiac Tamponade:

• Pericardial fluid limiting cardiac filling
• Beck's triad: Elevated JVP, muffled heart sounds, hypotension
• Pulsus paradoxus >20 mmHg

Hemodynamic Characteristics:

• Decreased cardiac output
• Elevated or normal CVP (except massive PE)
• Variable SVR
• Specific patterns depend on obstruction location

Diagnostic and Management Algorithm:

Obstructive Shock Evaluation ↓ Clinical assessment: • Sudden onset? • Recent surgery/immobilization? • Trauma history? ↓ Immediate interventions: • Tension pneumothorax → Needle decompression • Tamponade → Pericardiocentesis • Massive PE → Thrombolytics/embolectomy ↓ Confirmatory testing: • CTPA for PE • Echocardiography for tamponade • Chest X-ray for pneumothorax ↓ Definitive management: • Surgical intervention • Thrombolysis • Mechanical intervention

Specific Management Strategies:

Massive Pulmonary Embolism:

• Thrombolysis: Alteplase 100 mg IV over 2 hours
• Surgical embolectomy if contraindications to thrombolysis
• Catheter-directed therapy
• Anticoagulation: Heparin bolus + infusion

Tension Pneumothorax:

• Immediate needle decompression (2nd intercostal space, midclavicular line)
• Chest tube insertion (5th intercostal space, anterior axillary line)
• 100% oxygen administration

Cardiac Tamponade:

• Pericardiocentesis (subxiphoid approach)
• Pericardial window if recurrent
• Avoid positive pressure ventilation
• Fluid administration to maintain preload

Supportive Care:

• Avoid excessive positive pressure ventilation
• Maintain preload with cautious fluid administration
• Vasopressors if needed (norepinephrine preferred)
• Treat underlying cause definitively

Comprehensive hemodynamic monitoring is essential for shock classification, management guidance, and therapeutic response assessment. Modern monitoring techniques range from non-invasive to invasive methods, each providing specific hemodynamic parameters crucial for shock management.

Non-Invasive Monitoring:

Arterial Blood Pressure:

• Automated cuffs: Adequate for initial assessment
• Arterial line: Gold standard for continuous monitoring
• Mean arterial pressure (MAP) >65 mmHg target

Echocardiography:

• Bedside assessment of cardiac function
• Evaluates: Ejection fraction, wall motion, valve function
• Identifies: Tamponade, right heart strain, volume status

Pulse Pressure Variation (PPV):

• Predicts fluid responsiveness in mechanically ventilated patients
• PPV >13% suggests fluid responsiveness
• Not reliable in spontaneous breathing or arrhythmias

Invasive Monitoring:

Central Venous Pressure (CVP):

• Reflects right atrial pressure and preload
• Normal: 8-12 mmHg
• Limited utility as isolated parameter

Pulmonary Artery Catheter (Swan-Ganz):

• Provides comprehensive hemodynamic profile
• Measures: PCWP, cardiac output, SVR, PVR
• Reserved for complex cases due to complications

Hemodynamic Profiles by Shock Type:

Advanced Monitoring Technologies:

Transpulmonary Thermodilution (PiCCO):

• Less invasive than PA catheter
• Provides stroke volume variation, extravascular lung water
• Useful for fluid management optimization

Esophageal Doppler:

• Minimally invasive cardiac output monitoring
• Real-time assessment of fluid responsiveness
• Particularly useful in operative settings

Tissue Perfusion Markers:

• Lactate: Most important marker of tissue hypoperfusion
• Central venous oxygen saturation (ScvO₂): Normal >70%
• Mixed venous oxygen saturation (SvO₂): Normal 65-75%
• Capillary refill time: >2 seconds abnormal

Dynamic Assessment: Fluid responsiveness testing is crucial to avoid fluid overload:

• Passive leg raise test: Reversible fluid challenge
• Stroke volume variation: >12% suggests responsiveness
• Fluid challenge: 250-500 mL bolus with hemodynamic monitoring

Effective shock management requires a systematic, protocol-driven approach that prioritizes early recognition, rapid stabilization, and targeted therapy based on shock classification. The integration of clinical assessment, hemodynamic monitoring, and evidence-based interventions significantly improves patient outcomes.

Universal Shock Management Principles:

Initial Resuscitation (First Hour):

Shock Recognition ↓ ABCDE Assessment: • Airway management • Breathing support (O₂/ventilation) • Circulation (IV access, fluids) • Disability (neurologic assessment) • Exposure (temperature control) ↓ Hemodynamic Stabilization: • Target MAP ≥65 mmHg • Urine output >0.5 mL/kg/hr • Lactate clearance >10% ↓ Shock Classification: • Clinical + hemodynamic profile • Targeted therapy initiation

Goal-Directed Therapy:

• Early Goal-Directed Therapy (EGDT) targets:
  • CVP 8-12 mmHg
  • MAP ≥65 mmHg
  • ScvO₂ ≥70%
  • Hemoglobin ≥7 g/dL (70 g/L)

Fluid Therapy Optimization:

• Initial resuscitation: 30 mL/kg crystalloid within first 3 hours
• Reassess after each 500 mL bolus
• Switch to vasopressors if fluid-unresponsive
• Monitor for fluid overload complications

Vasopressor and Inotrope Selection:

First-line agents by shock type:

• Hypovolemic: Fluid replacement primary, vasopressors if refractory
• Cardiogenic: Dobutamine ± norepinephrine
• Distributive: Norepinephrine first-line
• Obstructive: Address mechanical cause, support with fluids/pressors

Monitoring and Endpoints:

Clinical Endpoints:

• Mental status improvement
• Urine output >0.5 mL/kg/hr
• Capillary refill <2 seconds
• Lactate clearance ≥10% per hour

Hemodynamic Endpoints:

• MAP ≥65 mmHg
• Cardiac index >2.5 L/min/m²
• ScvO₂ >70%
• Stroke volume variation optimization

Complications and Prevention:

Acute Complications:

• Acute kidney injury
• ARDS (acute respiratory distress syndrome)
• Multiorgan dysfunction syndrome
• Coagulopathy and bleeding

Prevention Strategies:

• Lung-protective ventilation (6 mL/kg ideal body weight)
• Stress ulcer prophylaxis
• DVT prophylaxis
• Glycemic control (glucose 140-180 mg/dL)
• Early mobilization when stable

Quality Measures:

• Time to antibiotic administration (<1 hour for sepsis)
• Lactate clearance rates
• Fluid balance optimization
• Vasopressor weaning protocols
• Length of ICU stay and mortality rates

Prognosis and Outcomes: Shock mortality varies by type and severity:

• Hypovolemic: 10-30% (depends on cause and response time)
• Cardiogenic: 40-50% (highest mortality)
• Septic: 20-40% (varies with organism and comorbidities)
• Obstructive: Variable (excellent if rapidly corrected)

Early recognition and appropriate management within the first 6 hours significantly impact survival and reduce long-term complications.